Description

Infliximab is a chimeric monoclonal antibody targeting TNF??, widely used in biomedical research to model and treat inflammatory and autoimmune diseases like rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and psoriasis. The Leiting® brand (CMAB008) is China’s first domestically manufactured infliximab biosimilar, produced via CHO cell expression with demonstrated similarity in safety and efficacy.

Provided in 100?mg/vial × 8 vials per box, this injectable formulation is ideal for researchers studying cytokine inhibition, inflammatory cascade modulation, and anti-TNF therapeutic mechanisms. Produced by Taizhou Mabpharm Co., Ltd. and approved under NMPA S20210025, this product also holds rapid GMP recognition for overseas markets .

?? For laboratory research only. Not for clinical, therapeutic, diagnostic, or veterinary use.

Infliximab for Injection Product Specifications

Infliximab for Injection Mechanism & Research Applications

Infliximab binds and neutralizes TNF??, disrupting inflammatory signaling pathways. Common research uses include:

• Autoimmune disease modeling (RA, AS, PsA, IBD)

• Cytokine release and NF??B signaling studies

• Inflammation, pain, and immune modulation research

• Preclinical evaluation of biosimilar efficacy and immunogenicity

Infliximab for Injection Side Effects (Observed in Research Models)

• Elevated infection susceptibility (bacterial, fungal)

• Infusion-like reactions: chills, fever, hypotension

• Hematologic changes, transient hepatic enzyme elevation

• Autoimmune-like effects such as lupus-like syndromes

• Rare risk of lymphoma or demyelinating disorders with high/chronic dosing

Infliximab for Injection Safety & Handling

• Use Restriction: Strictly for laboratory research; not for clinical or veterinary use

• PPE: Use gloves, lab coat, and safety goggles

• Storage: Keep refrigerated at 2–8?°C; do not freeze

• Preparation: Reconstitute under aseptic conditions

• Disposal: Follow institution’s hazardous biological waste protocols

Core Keywords

Infliximab biosimilar China, Leiting infliximab S20210025, 100?mg infliximab research, anti-TNF antibody lab use, Mabpharm infliximab CMAB008, wholesale infliximab vials, TNF?alpha inhibition research agent, lab-grade infliximab injection

Research Use Disclaimer

This product is intended only for laboratory research purposes. It is not approved for clinical, diagnostic, therapeutic, or veterinary use. Non-approved use may lead to regulatory and health risks. Users should follow institutional biosafety and handling protocols rigorously.